Results 1 to 10 of about 37,118 (221)

Europe's contribution to the evaluation of the use of systemic antimicrobials in the treatment of periodontitis

Periodontology 2000, EarlyView., 2023
Abstract This narrative review celebrates Europe's contribution to the current knowledge on systemically administered antimicrobials in periodontal treatment. Periodontitis is the most frequent chronic noncommunicable human disease. It is caused by dysbiotic bacterial biofilms and is commonly treated with subgingival instrumentation.
David Herrera, Arie Jan van Winkelhoff, Paula Matesanz, Katalina Lauwens, Wim Teughels   +4 more
wiley   +1 more source

Saarvienin A—A Novel Glycopeptide with Potent Activity against Drug‐Resistant Bacteria

Angewandte Chemie, EarlyView.
A structurally distinct glycopeptide, saarvienin A, represents a new family of glycopeptide antibiotics consisting of five sugar/aminosugar units connected to a halogenated peptide core. Saarvienin A overcomes vancomycin resistance and shows strong activity against drug‐resistant Gram‐positive bacteria, in particular, high‐priority pathogens such as ...
Amninder Kaur, Jaime Felipe Guerrero‐Garzón, Sari Rasheed, Martin Zehl, Franziska Fries, Bernd Morgenstern, Sergey B. Zotchev, Rolf Müller   +7 more
wiley   +2 more sources

Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Moxifloxacin is a priority drug for treating rifampicin‐resistant tuberculosis (RR‐TB). We assessed the pharmacokinetics of a child‐friendly, dispersible 100 mg tablet moxifloxacin formulation (dispersed in water) compared to the standard 400 mg non‐dispersible formulation (crushed and suspended in water) in children and evaluated current dosing ...
Megan Palmer, Yuanxi Zou, Anneke C. Hesseling, Louvina van der Laan, Ingrid Courtney, Aarti A. Kinikar, Naresh Sonkawade, Mandar Paradkar, Vandana Kulkarni, Dessa Jean O. Casalme, Melchor V. G. Frias, Heather Draper, Lubbe Wiesner, Mats O. Karlsson, Paolo Denti, Elin M. Svensson, Anthony J. Garcia‐Prats   +16 more
wiley   +2 more sources

Promising Prodiginins Biological Activities

Chemistry &Biodiversity, EarlyView.
ABSTRACT Prodiginins are a large family of at least 34 pyrrolic compounds, including the well‐studied red pigment prodigiosin. Prodiginins are produced by several microorganisms displaying broad biological activities, including antimicrobial, antiviral, antiparasitic, antiproliferative, and immunosuppressive activities.
María F. Ladetto, Melisa E. Gantner, Boris E. Rodenak‐Kladniew, Santiago Rodriguez, María L. Cuestas, Alan Talevi, Guillermo R. Castro   +6 more
wiley   +1 more source

Bioactives From Brown Algae: Antioxidant, Anti‐Inflammatory, Anticancer, and Antimicrobial Potential

ChemBioEng Reviews, EarlyView.
This review explores key bioactives in brown algae and their antioxidant, anti‐inflammatory, anticancer, and antimicrobial properties. Covering studies from 2014 to 2024, it highlights their relevance in pharmaceuticals, nutraceuticals, cosmetics, and foods, while addressing challenges and future directions to unlock their full potential.
Irvin Fonseca‐Barahona, Kaveh Shahbaz, Saeid Baroutian   +2 more
wiley   +1 more source

Label‐Free Photonic Biosensors: Key Technologies for Precision Diagnostics

ChemistryEurope, EarlyView.
Photonic biosensors are versatile technologies promising unique advantages to improve current diagnosis workflows. On‐going research is directed to systems integration and automation as well as enhancing assay performance. Advances in bioengineering, material sciences, and photonics engineering will be the key toward their eventual implementation as ...
Maria Soler, Laura M. Lechuga
wiley   +1 more source

Isoniazid‐Dihydropyrimidinone Molecular Hybrids: Design, Synthesis, Antitubercular Activity, and Cytotoxicity Investigations with Computational Validation

ChemMedChem, EarlyView.
Antitubercular evaluation of a novel library of isoniazid‐dihydropyrimidinone molecular hybrids (8a–8n) discloses a potent compound with MIC = 0.39μg mL−1 against M. tuberculosis mc26230. Cytotoxicity, stability, and in silico studies, including molecular docking and ADME/T (absorption, distribution, metabolism, excretion, and toxicity) analysis ...
Gobind Kumar, Pule Seboletswe, Sahil Mishra, Neha Manhas, Safiyah Ghumran, Nagaraju Kerru, Françoise Roquet‐Banères, Maëlle Foubert, Laurent Kremer, Gaurav Bhargava, Parvesh Singh   +10 more
wiley   +1 more source

Synthesis, Antimycobacterial Activity and Computational Insight of novel 1,4‐Benzoxazin‐2‐one Derivatives as Promising Candidates Against Multidrug‐Resistant M. tuberculosis

ChemMedChem, Accepted Article.
To search for new antitubercular agents, we have designed, synthesized, and evaluated a series of 1,4‐benzoxazinone‐based compounds. These molecules showed potent antimycobacterial activity, with MIC between 2 and 8 μg/mL. This interesting profile included activity against several drug‐resistant strains and minimal cytotoxicity against mammalian Vero ...
Daniele Zampieri, Maria Grazia Mamolo, Emanuele Carosati, Diletta Pasin, Alessandro De Logu, Gianluigi Cabiddu, Marko Jukic   +6 more
wiley   +1 more source

Is Mycobacterial InhA a Suitable Target for Rational Drug Design?

ChemMedChem, EarlyView.
InhA is the target of isoniazid, a first‐line antituberculosis drug. Isoniazid is, in fact, a prodrug that needs to be activated. Researchers are trying to develop direct inhibitors of InhA. This includes the resolution of crystallographic structures. The Protein Data Bank contains over a hundred InhA structures.
Julien Rizet, Laurent Maveyraud, David Rengel, Valérie Guillet, Gabriel Publicola, Frédéric Rodriguez, Christian Lherbet, Lionel Mourey   +7 more
wiley   +1 more source

Hybrid Molecules as Efficient Drugs against Multidrug‐Resistant Malaria Parasites

ChemMedChem, EarlyView.
Among hybrid molecules currently developed as antimalarial drug candidates, emoquine‐1 exhibits high activity against all the multidrug‐resistant Plasmodium strains tested up to now, including artemisinin‐resistant quiescent parasites, critical parameters for promising antimalarial drugs. It is also curative in mouse malaria.
Anne Robert, Lucie Paloque, Jean‐Michel Augereau, Flore Nardella, Michel Nguyen, Bernard Meunier, Françoise Benoit‐Vical   +6 more
wiley   +1 more source